Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.（RARE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · RARE · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
24
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Ultragenyx Pharmaceutical Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
RARE 季度内部人买卖趋势
RARE 内幕交易卖出 · RARE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · RARE CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
RARE 高管卖出股份 · RARE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Horn Howard CFO | Sale | 4,653 | $111K | Form 4 |
| May 14, 2026 | Fust Matthew K Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | SULIMAN SHEHNAAZ Director | Award | 7,751 | — | Form 4 |
| May 18, 2026 | SULIMAN SHEHNAAZ Director | Sale | 5,740 | $144K | Form 4 |
| May 14, 2026 | Ray Amrit Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | Sanders Corazon (Corsee) D. Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | NARACHI MICHAEL Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | WELCH DANIEL G Director | Award | 7,751 | — | Form 4 |
| May 14, 2026 | Dunsire Deborah Director | Award | 7,751 | — | Form 4 |
| May 5, 2026 | Crombez Eric EVP and Chief Medical Officer | Sale | 344 | $9K | Form 4 |
| May 1, 2026 | Horn Howard CFO | Sale | 4,683 | $117K | Form 4 |
| Apr 22, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Award | 20,241 | — | Form 4 |
| Apr 16, 2026 | KAKKIS EMIL D President & CEO · Director | Award | 76,745 | — | Form 4 |
| Apr 16, 2026 | Huang Dennis Karl See Remarks | Award | 23,116 | — | Form 4 |
| Apr 16, 2026 | Pinion John Richard See Remarks | Award | 23,116 | — | Form 4 |
| Apr 16, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Award | 28,895 | — | Form 4 |
| Apr 16, 2026 | Harris Erik EVP & Chief Commercial Officer | Award | 28,895 | — | Form 4 |
| Apr 16, 2026 | Crombez Eric EVP and Chief Medical Officer | Award | 34,674 | — | Form 4 |
| Apr 16, 2026 | Horn Howard CFO | Award | 34,674 | — | Form 4 |
| Apr 1, 2026 | Horn Howard CFO | Sale | 4,683 | $98K | Form 4 |
| Mar 6, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | 6,018 | $129K | Form 4 |
| Mar 10, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | 3,508 | $80K | Form 4 |
| Mar 1, 2026 | Pinion John Richard See Remarks | Award | 11,137 | — | Form 4 |
| Mar 2, 2026 | Pinion John Richard See Remarks | Sale | 10,029 | $229K | Form 4 |
| Mar 1, 2026 | Harris Erik EVP & Chief Commercial Officer | Award | 11,643 | — | Form 4 |
Huizenga Theodore Alan
SVP, Chief Accounting Officer
日期
Apr 22
股数
20,241
均价
—
总金额
—
Parschauer Karah Herdman
EVP and Chief Legal Officer
日期
Apr 16
股数
28,895
均价
—
总金额
—
Parschauer Karah Herdman
EVP and Chief Legal Officer
日期
Mar 6
股数
6,018
均价
$21.40
总金额
$129K
Parschauer Karah Herdman
EVP and Chief Legal Officer
日期
Mar 10
股数
3,508
均价
$22.67
总金额
$80K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 RARE 内幕交易
RARE 内幕交易
Ultragenyx Pharmaceutical Inc.（RARE）内幕交易数据来源于公司内部人（包括Horn Howard (CFO), Huizenga Theodore Alan (SVP, Chief Accounting Officer), Parschauer Karah Herdman (EVP and Chief Legal Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。RARE内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Ultragenyx Pharmaceutical Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
RARE 内幕交易 · 5个问题Ultragenyx Pharmaceutical Inc.（RARE）的内部人包括高管和董事，如Horn Howard (CFO), Huizenga Theodore Alan (SVP, Chief Accounting Officer), Parschauer Karah Herdman (EVP and Chief Legal Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026